Swine Flu Vaccine – A Public Health Experiment

What do human brain and nerve tissues, Gulf War Syndrome, some health supplements and GlaxoSmithKline’s new swine flu vaccine adjuvant all have in common? The answer: squalene. Its presence in fatty tissues and supplements is generally benign or beneficial; its presence in GSK’s vaccine is morbid.

GlaxoSmithKline (GSK) holds the contract to supply Canada’s pandemic H1N1 vaccine – a vaccine containing an unlicensed additive, specifically the AS03 squalene based adjuvant. AS03 is designed to stimulate a dramatically increased immune response which results in less vaccine antigen being required in each vaccine dose.

Read the full story at The Vaccination Risk Awareness Network